Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...
Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring Monday after the clinical-stage biopharmaceutical company reported positive topline data from a weight loss drug trial. The positive ...
GLP-1 agonist drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide are set to become all-time best-selling drugs. Structure Therapeutics has entered the race with an oral GLP-1 candidate, ...
G protein-coupled receptors (GPCRs) are essential for cell signal transduction and comprise the largest drug target protein family. Upon agonist stimulation, these receptors activate multiple ...
Hosted on MSN
Structure Therapeutics Inc. - Depositary Receipt (GPCR) price target increased by 21.89% to 94.31
) has been revised to $94.31 / share. This is an increase of 21.89% from the prior estimate of $77.37 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On December 19, H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback